The main purpose of this study is to explore if the combination of autologous NK cell infusion and chemotherapy can increase the therapeutic efficiency in the treatment of non-small cell lung cancer compared with chemotherapy alone.
Natural killer cells play an important role in the anti-tumor process mediated by innate immunity. However, past researches showed dissatisfactory clinical outcome in clinicaltrials using autologous NK cell infusion alone. With the expectation that the combination of autologous NK cell infusion and chemotherapy may increase the therapeutic efficiency of chemotherapy alone in cancer treatment, the investigators design and conduct this randomized controlled trial in the treatment of non-small cell lung cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
104
Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9,q28d\*4
135-175mg/m2,q28d\*4
AUC=5,q28d\*4
Southwest Hospital of Third Millitary Medical University
Chongqing, Chongqing Municipality, China
RECRUITINGNumber of participants responding to treatment
Response evaluation of treatment with chest CT scan is assessed by RECIST 1.1
Time frame: 4 months
Progress free survival(PFS) time
Time frame: 2 years
Overall survival time
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.